Blood Test Measures Hepatic Fibrosis Progression
By LabMedica International staff writers Posted on 20 Jan 2015 |
Viral hepatitis is the most prevalent infectious disease in Japan, affecting some three million people and left untreated, the condition can develop into severe illness as it progresses toward liver cell carcinoma.
As chronic hepatitis advances toward liver cell carcinoma, the amount of fiber-rich tissue in the liver increases and hepatic function gradually declines. An important part of the treatment process for viral chronic hepatitis is determining the degree of hepatic fibrosis. The typical testing process involves taking a biopsy of the liver tissue, requiring a patient to be hospitalized because of its high invasiveness. This places a substantial burden on the patient on both the physical and economic fronts.
A hepatic fibrosis test reagent called HISCL M2BPGi Assay Kit (Sysmex; Kobe, Japan) was developed for testing the degree of viral hepatitis-induced disease during blood testing and is to be used on automated immunoassay systems—the Sysmex HISCL-Series HISCL-5000/2000i/800. The assay requires only a blood sample to determine within just about 17 minutes the status of progression of hepatic fibrosis to chronic hepatitis and cirrhosis of the liver, which has been suspected to be a cause of hepatocellular carcinoma. The hepatic fibrosis test reagent HISCL M2BPGi Assay Kit has been approved for insurance coverage domestically as of January 1, 2015.
The assay measures Mac-2 Binding Protein (M2BP) Glycosylation isomer and uses a chemiluminescent enzyme-linked immunoassay using a two-step sandwich method. Sugar chains, the linked monosaccharides that link to the surface of a cell or a protein, are sometimes described as "cell and protein costumes." Their roles include the transmission of information specific to individual cells and intercellular communications. A glycosylation marker is a biomarker that targets structural changes in sugar changes present in glycoproteins. The product will be introduced to the domestic market with the focus on medical facilities and diagnostic centers. Introductions to Asian countries, specifically China with its large number of liver disease patients, will follow in order.
Related Links:
Sysmex
As chronic hepatitis advances toward liver cell carcinoma, the amount of fiber-rich tissue in the liver increases and hepatic function gradually declines. An important part of the treatment process for viral chronic hepatitis is determining the degree of hepatic fibrosis. The typical testing process involves taking a biopsy of the liver tissue, requiring a patient to be hospitalized because of its high invasiveness. This places a substantial burden on the patient on both the physical and economic fronts.
A hepatic fibrosis test reagent called HISCL M2BPGi Assay Kit (Sysmex; Kobe, Japan) was developed for testing the degree of viral hepatitis-induced disease during blood testing and is to be used on automated immunoassay systems—the Sysmex HISCL-Series HISCL-5000/2000i/800. The assay requires only a blood sample to determine within just about 17 minutes the status of progression of hepatic fibrosis to chronic hepatitis and cirrhosis of the liver, which has been suspected to be a cause of hepatocellular carcinoma. The hepatic fibrosis test reagent HISCL M2BPGi Assay Kit has been approved for insurance coverage domestically as of January 1, 2015.
The assay measures Mac-2 Binding Protein (M2BP) Glycosylation isomer and uses a chemiluminescent enzyme-linked immunoassay using a two-step sandwich method. Sugar chains, the linked monosaccharides that link to the surface of a cell or a protein, are sometimes described as "cell and protein costumes." Their roles include the transmission of information specific to individual cells and intercellular communications. A glycosylation marker is a biomarker that targets structural changes in sugar changes present in glycoproteins. The product will be introduced to the domestic market with the focus on medical facilities and diagnostic centers. Introductions to Asian countries, specifically China with its large number of liver disease patients, will follow in order.
Related Links:
Sysmex
Read the full article by registering today, it's FREE!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
- Free digital version edition of LabMedica International sent by email on regular basis
- Free print version of LabMedica International magazine (available only outside USA and Canada).
- Free and unlimited access to back issues of LabMedica International in digital format
- Free LabMedica International Newsletter sent every week containing the latest news
- Free breaking news sent via email
- Free access to Events Calendar
- Free access to LinkXpress new product services
- REGISTRATION IS FREE AND EASY!
Sign in: Registered website members
Sign in: Registered magazine subscribers
Latest Immunology News
- AI Predicts Tumor-Killing Cells with High Accuracy
- Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies
- AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell
- Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment
- Testing Method Could Help More Patients Receive Right Cancer Treatment
- Groundbreaking Test Monitors Radiation Therapy Toxicity in Cancer Patients
- State-Of-The Art Techniques to Investigate Immune Response in Deadly Strep A Infections
- Novel Immunoassays Enable Early Diagnosis of Antiphospholipid Syndrome
- New Test Could Predict Immunotherapy Success for Broader Range Of Cancers
- Simple Blood Protein Tests Predict CAR T Outcomes for Lymphoma Patients
- Cell Sorter Chip Technology to Pave Way for Immune Profiling at POC
- Chip Monitors Cancer Cells in Blood Samples to Assess Treatment Effectiveness
- Automated Immunohematology Approaches Can Resolve Transplant Incompatibility
- AI Leverages Tumor Genetics to Predict Patient Response to Chemotherapy
- World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw
- Predictive T-Cell Test Detects Immune Response to Viruses Even Before Antibodies Form